Hepatitis C virus seroconversion among young injection drug users: Relationships and risks

Journal of Infectious Diseases

Volumn 186, Issue 11, 2002, Pages 1558-1564

  Hahn, Judith A ^a,d   Page Shafer, Kimberly ^a   Lum, Paula J ^a   Bourgois, Philippe ^b   Stein, Ellen ^a   Evans, Jennifer L ^a   Busch, Michael P ^a,c   Tobler, Leslie H ^c   Phelps, Bruce ^e   Moss, Andrew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Blood Centers of the Pacific   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; DEMOGRAPHY; DRUG ABUSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; INJECTION; MAJOR CLINICAL STUDY; MALE; MONEY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INCIDENCE; MALE; NEEDLE SHARING; PROSPECTIVE STUDIES; RISK FACTORS; SEXUAL PARTNERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0036890620     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345554     Document Type: Article

References (43)

1. Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994; 271:115-20.
2. Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994; 8:223-31.
3. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic: Injecting drug users in New York City, 1984 through 1992. JAMA 1994; 271:121-7.
4. Longshore D, Annon J, Anglin MD. Long-term trends in self-reported HIV risk behavior: Injection drug users in Los Angeles, 1987 through 1995. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:64-72.
5. van Ameijden EJ, Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS 1998; 12:625-33.
6. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: A cohort study. AIDS 2000; 14:605-11.
7. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment a risk factor for hepatitis C. Am J Public Health 2001; 91:42-6.
8. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study. BMJ 1998; 317:433-7.
9. Brunton C, Kemp R, Raynel P, Harte D, Baker M. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. N Z Med J 2000; 113:98-101.
10. van Ameijden EJ, Van den Hoek JA, Mientjes GH, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993; 9:255-62.
11. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35:3274-7.
12. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust 1997; 167:17-20.
13. Thorpe L, Ouellet L, Hershow R, Bailey S, Williams I, Monterosso E. The multiperson use of non-syringe injection equipment and risk of hepatitis C infection in a cohort of young adult injection drug users, Chicago 1997-1999. Ann Epidemiol 2000; 10:472-3.
14. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155:645-53.
15. Hahn J, Page-Shafer K, Lum P, Ochoa K, Moss A. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34:180-7.
16. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquit Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1):S11-9.
17. Bluthenthal R, Kral A, Erringer E, Edlin B. Drug paraphernalia and injection-related infectious disease risk among drug injectors. J Drug Issues 1999; 29:1-16.
18. Koester SK. Copping, running, and paraphernalia laws: Contextual variables and needle risk behavior among injection drug users in Denver. Hum Org 1994; 53:287-95.
19. Zule WA. Risk and reciprocity: HIV and the injection drug user. J Psychoactive Drugs 1992; 24:243-9.
20. Bourgois P. The moral economies of homeless heroin addicts: Confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments. Subst Use Misuse 1998; 33:2323-51.
21. Murphy S. Intravenous drug use and AIDS: The social economy of needle sharing. Contemp Drug Probl 1987; 14:373-96.
22. Barnard MA. Needle sharing in context: Patterns of sharing among men and women injectors and HIV risks. Addiction 1993; 88:805-12.
23. Neaigus A, Friedman SR, Goldstein M, Ildefonso G, Curtis R, Jose B. Using dyadic data for a network analysis of HIV infection and risk behaviors among injecting drug users. NIDA Res Monogr 1995; 151:20-37.
24. Koester S, Booth R, Wiebel W. The risk of HIV transmission from sharing water, drug-mixing containers and cotton filters among intravenous drug users. Int J Drug Policy 1990; 1:28-30.
25. Needle RH, Coyle S, Cesari H, et al. HIV risk behaviors associated with the injection process: Multiperson use of drug injection equipment and paraphernalia in injection drug user networks. Subst Use Misuse 1998; 33:2403-23.
26. Grund JP, Friedman SR, Stern LS, et al. Syringe-mediated drug sharing among injecting drug users: Patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med 1996; 42:691-703.
27. Koester S, Booth RE, Zhang Y. The prevalence of additional injection-related HIV risk behaviors among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:202-7.
28. McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: Assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1):S25-9.
29. van Beck I, Buckley R, Stewart M, MacDonald M, Kaldor J. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 1994; 70:321-4.
30. Diaz T, Des Jarlais DC, Perlis TE, et al. Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001; 91:23-30.
31. Kral AH, Lorvick J, Edlin BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr 2000; 24:162-7.
32. Stark K, Müller R, Bienzle U, Guggenmoos-Holzmann I. Frontloading: A risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS 1996; 10:311-7.
33. Thorpe L, Ouellet L, Levy J, Williams I, Monterroso E. Hepatitis C virus infection: Prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis 2000; 182:1588-94.
34. Bourgois, P. Theory, method, and power in drug and HIV-prevention research: A participant-observer's critique. Subst Use Misuse 1999; 34:2155-72.
35. Goffin E, Pirson Y, Cornu C, Jadoul M, van Ypersele de Strihou C. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994; 343:854.
36. Courouce AM, Bouchardeau F, Girault A, Le Marrec N. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994; 343:853-4.
37. Uyttendaele S, Claeys H, Mertens W, Verhaert H, Vermylen C. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994; 66:122-9.
38. Tabor E, Yu MY, Hewlett I, Epstein JS. Summary of a workshop on the implementation of NAT to screen donors of blood and plasma for viruses. Transfusion 2000; 40:1273-5.
39. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165-8.
40. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001; 8:200-6.
41. Evans JL, Hahn JA, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco. The UFO study. J Urban Health (in press).
42. Guydish J, Moore L, Gleghorn A, Davis T, Sears C, Harcourt J. Drug abuse treatment on demand in San Francisco: Preliminary findings. J Psychoactive Drugs 2000; 32:363-70.
43. McKeganey N, Friedman SR, Mesquita F. The social context of injectors' risk behavior. In: Stimson GV, Des Jarlais DC, Ball AL, eds. Drug Injecting and HIV Infection. London: UCL Press, 1998:22-41.